Daily scan of every earnings reaction moving 20% or more, either direction. Ranked within each column by mismatch -- overreactions and mixed calls first, clean justified moves last -- so the ones worth reading first are on top.
| Ticker | Move | Verdict | Sector |
|---|
AIRS — AirSculpt Technologies, Inc. (-25.3%)
AirSculpt reported a significant EPS miss of -233.3% (actual -$0.02 vs. estimate +$0.015) and a modest revenue miss of -2.8% ($42.9M vs. $44.1M estimate), triggering a 25.3% stock drop. However, the underlying operational picture was more stable than the headline numbers suggest: same-center case volume grew 1.0% for the second consecutive quarter, same-center revenue was flat (vs. prior year), and adjusted EBITDA of $4.9M was only down 15.6% from $5.8M a year ago. The company reaffirmed full-year 2026 revenue guidance at $151–$157M but reduced adjusted EBITDA outlook to $12–$14M (vs. prior $15–$18M implied range), representing meaningful margin compression but not a business implosion. Management highlighted $30M in debt reduction, $10M cash buildup, and a new AlloClae partnership to broaden the addressable market. A 25% decline on a 2.8% revenue miss and a non-GAAP EBITDA downgrade appears to price in existential concerns that the press release and stabilizing same-center metrics don't fully justify—this is likely an overreaction driven by momentum selling in a weak cosmetic-procedure category and cash-burn anxiety.
View AIRS →NABL — N-able, Inc. (-22.6%)
N-able reported a small EPS beat (+1.7%) at $0.10 vs. $0.0983 estimate, but stumbled badly on revenue with a -7.0% miss ($128.4M actual vs. $138.1M estimate)—a $9.7M shortfall. However, the company's operational narrative remains constructive: Q2 ARR grew 6% YoY at constant currency to $544.5M, subscription revenue grew 6.1% YoY, and adjusted EBITDA margin held steady at 28.9%. Management raised full-year 2026 ARR guidance to $562–$565M (4–5% growth), appointed a new Chief Revenue Officer to accelerate growth, launched AI-powered security features, and reiterated confidence in the market opportunity. The -22.6% stock drop appears disproportionate to a single quarter's revenue miss when underlying subscription and ARR metrics remain on track, profitability is intact, and forward guidance was actually raised. A 7% revenue miss alone does not typically justify a 23% equity destruction when margins, retention, and long-term guidance all point to steady execution.
View NABL →ACH — Accendra Health, Inc. (-30.1%)
Accendra Health reported a Q2 EPS miss of -$0.19 versus consensus -$0.084 (a 126.6% negative surprise) and a modest revenue miss of $613.2M versus $628.7M estimate (-2.5%), while guiding FY2026 revenue to $2.45–$2.55B and adjusted EBITDA to $300–$320M—both implying sequential deterioration from prior expectations. Management highlighted $385M in debt reduction and $125M+ in annualized cost savings from a major payor exit, plus growth initiatives expected to accelerate in 2027, yet free cash flow guidance was downgraded to breakeven-to-slightly-positive from the prior implied positive trajectory. The 30% stock drop appears partially justified by the earnings miss and negative free cash flow outlook, but is amplified by CEO Ed Pesicka's announced retirement by year-end 2026—a material governance uncertainty that compounds investor concerns about execution risk during a transition period. The combination of a large EPS miss (126.6%), deteriorating cash flow, and imminent leadership change represents genuine structural headwinds, though the magnitude of the decline also reflects heightened uncertainty pricing rather than quantifiable financial deterioration alone.
View ACH →SION — Sionna Therapeutics, Inc. (-90.5%)
Sionna Therapeutics reported that its lead Phase 2a trial (PreciSION CF) for SION-719 failed to meet its primary efficacy endpoint, achieving only a -1.0 mmol/L mean placebo-adjusted sweat chloride reduction with a p-value of 0.7 (statistically insignificant), and the company announced it will not advance SION-719 as an add-on therapy to standard of care. The company identified potential confounders including higher-than-expected variability in sweat chloride levels and inconsistent Trikafta exposure between treatment arms, but these explanations do not salvage the failed outcome. While a companion Phase 1 dual-combination trial (SION-451 + SION-2222) met safety and pharmacokinetic endpoints, the company explicitly stated it is "evaluating next steps" for this program and intends to "take actions to preserve capital"—language signaling meaningful operational uncertainty and likely reduced investment in pipeline advancement. For a clinical-stage biotech with a single meaningful pipeline asset, a complete Phase 2 failure with no clear path forward and capital preservation messaging justifies a severe repricing; a 90% decline reflects the elimination of near-term value creation and heightened execution risk on the remaining combination approach.
View SION →QTRX — Quanterix Corporation (-40.7%)
Quanterix reported Q2 revenue of $32.9M, missing analyst estimates by 12.2% ($37.5M expected), while EPS came in at -$0.45 versus -$0.41 expected—a 9.8% miss. The company slashed full-year 2026 guidance from $169–174M to $142–148M (a 16% reduction at the midpoint) and pushed cash-flow break-even from 2026 to 2027, signaling operational distress beyond quarterly noise. Management cited "execution challenges and continued market softness" and took "immediate and significant action" including senior leadership restructuring and a $26.9M goodwill impairment on the Akoya acquisition. While the company ended with $96.9M cash and improved adjusted cash burn, the magnitude of the guidance miss—nearly $27M off the midpoint—combined with delayed profitability, compressed gross margin guidance (48–50% vs. prior 49–53%), and clear admission of commercial underperformance justifies material multiple compression. A 41% single-day drop on a 12% revenue miss and 16% full-year guide cut reflects appropriate re-pricing of a struggling life-sciences company facing both near-term execution issues and structural market headwinds.
View QTRX →